Abstract
Pharmacokinetics and drug metabolism play an important role as determinants of in vivo drug action. The CYP450 enzyme family plays a determinant role in the biotransformation of a vast number of structurally diverse drugs. Many drug interactions are a result of the inhibition or induction of CYP enzymes. The non-compartmental pharmacokinetic analysis is the most used method for analyzing data from a drug interaction study. Compartmental analysis can be also useful and sometimes more informative than non-compartmental analysis. Many efforts to reduce polypharmacy are important, and pharmacokinetic tools used to study the mechanism of drug-drug interactions may help in a better management of pharmacotherapy including the avoidance of clinically relevant drug interactions.
Keywords: Pharmacokinetics, Metabolism, Drug interactions
Current Clinical Pharmacology
Title: Pharmacokinetics and Metabolic Drug Interactions
Volume: 1 Issue: 1
Author(s): Sorin E. Leucuta and Laurian Vlase
Affiliation:
Keywords: Pharmacokinetics, Metabolism, Drug interactions
Abstract: Pharmacokinetics and drug metabolism play an important role as determinants of in vivo drug action. The CYP450 enzyme family plays a determinant role in the biotransformation of a vast number of structurally diverse drugs. Many drug interactions are a result of the inhibition or induction of CYP enzymes. The non-compartmental pharmacokinetic analysis is the most used method for analyzing data from a drug interaction study. Compartmental analysis can be also useful and sometimes more informative than non-compartmental analysis. Many efforts to reduce polypharmacy are important, and pharmacokinetic tools used to study the mechanism of drug-drug interactions may help in a better management of pharmacotherapy including the avoidance of clinically relevant drug interactions.
Export Options
About this article
Cite this article as:
Leucuta E. Sorin and Vlase Laurian, Pharmacokinetics and Metabolic Drug Interactions, Current Clinical Pharmacology 2006; 1 (1) . https://dx.doi.org/10.2174/157488406775268183
DOI https://dx.doi.org/10.2174/157488406775268183 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Evolving Mechanistic Concepts of Epileptiform Synchronization and their Relevance in Curing Focal Epileptic Disorders
Current Neuropharmacology Synthesis and Pharmacological Screening of Novel 1,3-Disubstituted 5-Pyrazolones as Anticonvulsant Agents
Current Bioactive Compounds Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Current Topics in Medicinal Chemistry Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Current Drug Targets Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Neuroimaging of Gut Nutrient Perception
Current Pharmaceutical Design Cyclooxygenase-2 in Synaptic Signaling
Current Pharmaceutical Design Studying the Ethno-Pharmacological Basis of Antiepileptic Activity of Medhya Rasayanas- A Nootropic Package From Ayurveda
Current Traditional Medicine Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews Three Decades of Valproate: A Current Model for Studying Autism Spectrum Disorder
Current Neuropharmacology The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Alkaloids of <i>Peganum harmala</i>: Anticancer Biomarkers with Promising Outcomes
Current Pharmaceutical Design The Quest for Eldorado: Development of Radioligands for In Vivo Imaging of Nicotinic Acetylcholine Receptors in Human Brain
Current Pharmaceutical Design Pycnogenol Protects against Pentylenetetrazole-Induced Oxidative Stress and Seizures in Mice
Current Clinical Pharmacology 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Current Pharmaceutical Design MicroRNA 155, Factor XIII and Type 2 Diabetes Mellitus and Coronary Heart Disease
Current Diabetes Reviews Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Current Drug Abuse Reviews